Glenmark Pharmaceuticals Ltd. is Rated Buy

Current Rating and Its Significance

MarketsMOJO’s 'Buy' rating for Glenmark Pharmaceuticals Ltd. indicates a positive outlook on the stock, suggesting it is expected to deliver favourable returns relative to the broader market. This rating is based on a comprehensive evaluation of four key parameters: quality, valuation, financial trend, and technicals. Investors should understand that a 'Buy' rating reflects confidence in the company’s ability to sustain growth and generate shareholder value, while also considering current market conditions and company-specific factors.

Quality Assessment

As of 22 June 2026, Glenmark Pharmaceuticals maintains a strong quality grade, classified as 'good' by MarketsMOJO. This assessment is supported by the company’s robust operational performance and financial health. Notably, Glenmark exhibits a very low Debt to EBITDA ratio of 0.13 times, underscoring its strong capacity to service debt and maintain financial stability. This low leverage reduces risk and provides flexibility for future investments or navigating market uncertainties.

The company has also demonstrated consistent profitability, declaring positive results for the last three consecutive quarters. The latest six-month Profit After Tax (PAT) stands at ₹1,133.97 crores, reflecting an impressive growth rate of 103.40%. Such sustained earnings growth is a hallmark of quality, signalling effective management and competitive positioning within the Pharmaceuticals & Biotechnology sector.

Valuation Perspective

Glenmark’s valuation remains attractive as of 22 June 2026. The stock trades at a Price to Book (P/B) ratio of 5.9, which, while elevated, is considered reasonable given the company’s strong return metrics and growth prospects. The Return on Equity (ROE) is a healthy 26.9%, indicating efficient utilisation of shareholder capital to generate profits.

Importantly, the stock is trading at a discount relative to its peers’ average historical valuations, offering investors a compelling entry point. Over the past year, Glenmark has delivered a total return of 33.96%, while profits have surged by 125.6%. This combination results in a very low Price/Earnings to Growth (PEG) ratio of 0.2, signalling that the stock’s price growth has not yet fully priced in its earnings expansion, which is favourable for value-conscious investors.

Financial Trend and Performance

The financial trend for Glenmark Pharmaceuticals is decidedly positive. The company’s net sales for the nine months ending 22 June 2026 reached ₹13,718.08 crores, growing at a rate of 36.13%. This top-line expansion is complemented by an exceptionally high Return on Capital Employed (ROCE) of 40.16% for the half-year period, reflecting efficient capital deployment and strong operational profitability.

These metrics indicate that Glenmark is not only growing but doing so profitably and efficiently, which bodes well for sustained shareholder returns. The company’s ability to convert sales growth into robust earnings and returns on capital is a key driver behind the current 'Buy' rating.

Technical Outlook

From a technical perspective, Glenmark Pharmaceuticals is rated as 'mildly bullish'. This suggests that the stock’s price action and momentum indicators are generally positive, though not exhibiting extreme bullishness. The stock’s recent price movements show resilience, with a one-year return of 33.96% and a six-month gain of 7.37%, despite some short-term volatility such as a 1.14% decline on the latest trading day.

Institutional investors hold a significant 39.67% stake in the company, which often reflects confidence from well-resourced market participants who conduct thorough fundamental analysis. This institutional backing can provide price support and reduce volatility, further reinforcing the technical outlook.

Sector and Market Context

Operating within the Pharmaceuticals & Biotechnology sector, Glenmark is positioned in a midcap segment with strong growth potential. The sector is known for innovation-driven growth and resilience in economic cycles, which adds to the stock’s appeal. Glenmark’s inclusion among the top 1% of companies rated by MarketsMOJO across over 4,000 stocks highlights its exceptional standing in terms of quality and performance metrics.

What This Rating Means for Investors

For investors, the 'Buy' rating on Glenmark Pharmaceuticals Ltd. signals a recommendation to consider adding or holding the stock within their portfolios. The rating reflects a balanced view that the company’s fundamentals, valuation, and financial trends support further appreciation in share price, while the technical indicators suggest a stable to positive price trajectory.

Investors should note that while the rating was updated on 01 June 2026, the current financial data as of 22 June 2026 confirms the company’s strong position. This up-to-date analysis ensures that investment decisions are based on the latest available information rather than historical snapshots.

Given Glenmark’s strong earnings growth, attractive valuation metrics, and solid financial health, the stock remains a compelling option for those seeking exposure to the Pharmaceuticals & Biotechnology sector with a midcap growth focus. However, as with all investments, investors should consider their risk tolerance and portfolio diversification needs before making decisions.

Summary

In summary, Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, reflecting a positive outlook grounded in strong quality, attractive valuation, encouraging financial trends, and a mildly bullish technical stance. The company’s robust earnings growth, low leverage, and institutional support underpin this recommendation, making it a noteworthy candidate for investors seeking growth opportunities in the pharmaceutical space.

All financial metrics and returns referenced are current as of 22 June 2026, ensuring that the analysis reflects the latest market and company developments.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →